Abstract

Impact of treatment of iron deficiency anemia in inflammatory bowel disease: considerations in managed care

Am J Manag Care. 2021 Jul;27(11 Suppl):S219-S223. doi: 10.37765/ajmc.2021.88715.

Jeenal Patel 1

 
     

Author information

  • 1Formulary Design and Strategy, Oscar Health, Lakeland, FL. Email: jbpatel06@gmail.com.

Abstract

Inflammatory bowel disease (IBD) is commonly associated with iron deficiency anemia (IDA), with a multifactorial pathophysiology. Diagnosis of both IDA and IBD places patients at risk for poor quality of life, as well as increased hospitalization and healthcare utilization. Treatment of IDA involves iron repletion with either oral or intravenous iron products. When selecting therapy, the total expenses of care must be considered, including direct and indirect costs, as well as patient clinical outcomes.

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.